Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

*Open Heart*

<u>Disposition of participants</u>

```
                    ┌─────────────────────┐
                    │  Enrolled (n = 40)  │
                    └──────────┬──────────┘
                               │
                    ┌──────────▼──────────┐
                    │ Randomized (n = 40) │
                    └──────────┬──────────┘
              ┌────────────────┴────────────────┐
              ▼                                  ▼
```

| **Sequence AB (n=20)** | **Sequence BA (n=20)** |
|---|---|
| Period 1: 2-oxo-clopidogrel (40mg/10mg)<br>Period 2: Clopidogrel (300mg/75mg) | Period 1: Clopidogrel (300mg/75mg)<br>Period 2: 2-oxo-clopidogrel (40mg/10mg) |

| Discontinued patients (n = 2)<br>• Adverse events (n=2) | Discontinued patients (n = 1)<br>• Consent withdrawn (n=1) |
|---|---|

| Completed (n=18) | Completed (n = 19) |
|---|---|

*Note: A washout period of at least 14 days was maintained between the study periods*